treatment options for patients with tp53-mutated aml
Published 1 year ago • 1K plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:08
novel strategies to target p53-mutant hematological malignancies
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
3:56
treatment approaches for patients with tp53-mutated mcl
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
1:13
the challenges of treating patients with mpns who possess a tp53 mutation
-
1:57
the benefit of allogeneic transplantation in patients with tp53-mutated aml
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
2:41
advances in the treatment and prognosis of ttp
-
13:31
p53 structure and function - cell cycle regualtion & apoptosis
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
1:39
treatment approaches for patients with tp53m aml ineligible for high intensity chemotherapy
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:27
tp53-aberrant mcl: challenges and treatment approaches
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
2:39
allogeneic therapy for the treatment of refractory hematological malignancies
-
1:13
the importance of improving the management of cardiotoxicity when treating cll
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
2:24
the challenges of treating tp53-mutated aml and mds
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml